Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2601–2650 of 34667
On April 25, 2025, Ronald J. Naples resigned from the Board of Directors (the “Board”) of PENN Entertainment, Inc. (the “Company”) effective immediately.
the Board approved, effective April 28, 2025, an increase in the size of the Board from seven (7) directors to eight (8) directors and appointed Merdad Parsey, M.D., Ph.D. to fill the newly created vacancy on the Board
On April 23, 2025, Carl L. Gordon, Ph.D., CFA notified the board of directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) of his decision not to stand for re-election to the Board at the end of his current term at the Company’s 2025 annual meeting of stockholders currently expected to be held on June 18, 2025
Dr. Backstrom also resigned as a member of the Board on the Transition Date.
On April 22, 2025, Noelle K. Eder notified the Board of Directors of Ameren Corporation (the "Company") that she was resigning as a director of the Company, effective as of May 6, 2025.
On April 28, 2025 , the Board appointed Mr. Carty to the Board as a Class I director, with a term expiring at the 2026 Annual Meeting.
On April 28, 2025, the Board of Directors (the “Board”) of Metsera, Inc. (the “Company”) appointed Jon P. Stonehouse to the Company’s Board, effective immediately.
On April 23, 2025, in connection with the IPO, R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan (collectively with E. Scott Crist, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On April 23, 2025, in connection with the IPO, R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan (collectively with E. Scott Crist, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On April 23, 2025, in connection with the IPO, R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan (collectively with E. Scott Crist, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On April 23, 2025, in connection with the IPO, R. Greg Smith, Andrew Clark, Harvin Moore, and Aruna Viswanathan (collectively with E. Scott Crist, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On April 24, 2025, Daniel Springer notified Docusign, Inc. (the “Company”) of his resignation from the Company’s Board of Directors, effective immediately.
In addition, on April 30, 2025, the size of the Board will be further reduced to nine members following the previously announced retirement of Jon Kessler from the Board.
On April 22, 2025, Paul Black resigned as a member of the Board of Directors (the “Board”) of HealthEquity, Inc. (the “Company”).
On April 25, 2025, FitLife Brands, Inc. (the “ Company ”) appointed Shannon Pappas as an independent member of the Board of Directors of the Company (the “ Board ”), to serve until the next annual meeting of shareholders or until her successor is elected and qualified.
Todd Ordal, who tendered his resignation from his role as a member of the Board, effective April 25, 2025.
On April 22, 2025, Mr. Christopher R. Curia, age 69, announced his intention to retire from the board of directors (the “Board”) of Sunoco GP LLC (the “General Partner”), the general partner of Sunoco LP (the “Partnership”), effective May 1, 2025.
On April 25, 2025, Amrit Nagpal notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of April 25, 2025.
the Board was notified by each of Michael Idelchik and Bradley Kreger of their decisions to resign as directors of the Company
the Board was notified by each of Michael Idelchik and Bradley Kreger of their decisions to resign as directors of the Company
appointed each of Jason Lloyd and Kenneth Thieneman to serve as directors of the Board to fill the vacancies created by the resignations described below.
appointed each of Jason Lloyd and Kenneth Thieneman to serve as directors of the Board to fill the vacancies created by the resignations described below.
On the same date, the Board appointed Nicola Caiano to replace Ms. Halford on the Board.
On April 26, 2025, Mary Ann Halford resigned from the Board of Directors (the “Board”) of Eightco Holdings Inc. (the “Company”).
On April 23, 2025, Alisa Lask notified the Board of Directors (the “Board”) of Nephros, Inc. (the “Company”) that she will not stand for re-election to the Board at the Company’s annual meeting of stockholders scheduled to be held on June 16, 2025 (the “2025 Annual Meeting”).
On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.
On April 28, 2025, the Board of Directors (the “Board”) of Tharimmune, Inc. (the “Company”) increased the size of the Board to nine members and appointed each of Clay Kahler and Gary Stetz as members of the Board.
Additionally, Mr. Alexandr Chiciuc, Director, also resigned.
Effective April 24, 2025, Carrie Schwarz stepped down as a director of the Company.
Mr. Shafer has also been elected to the Board of Directors effective July 1, 2025.
resigned as a member of the Board
On April 24, 2025, the Board also appointed Mr. Doyle as a director to serve until the 2027 Annual Meeting of Shareholders and until his successor is elected and qualified, effective as of the Transition Effective Date.
On April 21, 2025, Christina McCarthy, a member of the board of directors (the "Board") since 2023, notified the Company that she will not stand for re-election as a director of the Company upon the expiration of her current term, which expires at the Company's 2025 Annual Meeting of Shareholders.
The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.
Separately, on April 21, 2025, Marna C. Whittington, Ph.D., a member of the Board, the Compensation Committee of the Board, and a member and chair of the Audit Committee of the Board, informed the Company of her decision to not stand for re-election to the Board at the Company’s 2025 Annual Meeting.
Prabha Fernandes, Ph.D., FIDSA, a member of the Board of Directors (the “Board”) of Ocugen, Inc. (the “Company”), a member and chair of the Compensation Committee of the Board, a member of the Audit Committee of the Board and the Science and Technology Committee of the Board, informed the Company that she is resigning from the Board effective at the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).
The Board plans to nominate Satish Chandran, Ph.D. and Blaise Coleman for election to the Board at the 2025 Annual Meeting to replace Dr. Fernandes and Dr. Whittington.
and Mr. Tracy Bolt as lead independent director.
On April 23, 2025, the Board of Directors (the “Board”) of World Kinect Corporation (the “Company”) appointed Jeffrey M. Kottkamp as a director of the Company.
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
Julien Lederman and Ofir Baharav, who constituted the directors of Merger Sub as of immediately prior to the Effective Time, became the directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
Julien Lederman and Ofir Baharav, who constituted the directors of Merger Sub as of immediately prior to the Effective Time, became the directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
each of Alan Masarek, Shai Terem, Edward T. Anderson, Michael Medici, Paul Milbury, Carol Meyers, Antonio Rodriguez, Aaron VanDevender and George Riedel resigned from the Board and from any and all committees thereof on which they served and ceased to be directors of the Company
On April 25, 2025, Mark Iwicki provided notice of his resignation from the board of directors (the “Board”) of Q32 Bio Inc. (the “Company”), effective as of December 31, 2025
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.